Gentian Diagnostics AS

GENT.OL

Medical - Specialties · Healthcare

Exchange

Oslo Stock Exchange

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Dividends

Weak

Track this stock — start free trial

Winston Score History

The full picture

Gentian Diagnostics is a Norwegian medical company that makes diagnostic reagents — chemical substances used by hospital laboratories and clinics to run blood tests. Their main products are particle-enhanced turbidimetric immunoassay (PETIA) reagents, which help doctors measure specific proteins in a patient's blood to detect conditions like heart disease and kidney problems. The company sells primarily to clinical laboratories and hospital systems, mostly across Europe.

Gentian earns revenue by selling its reagent products to diagnostic instrument manufacturers and laboratories, often through supply agreements where customers reorder consumables regularly. The company operates mainly in Europe but is working to expand into larger markets like the United States and Asia. Its competitive position rests on specialized chemistry know-how and partnerships with instrument makers, though with negative operating and returns on capital, it is not yet consistently profitable. The key growth driver is winning new commercial partnerships and expanding its cystatin C and cardiac biomarker tests into broader global markets.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+14.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+323.1% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

49.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~6 years

kr 79M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

kr 79M cash & investments at current burn rate

Growth context

Gentian Diagnostics AS is growing revenue at 14% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

55.4%

Premium pricing power — 55.4% gross margin

Profit after running costs

Operating Margin

11.9%

Modest — 11.9% operating margin

Return on the money invested

ROCE

-4.6%

Weak — -4.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+11.5%

Steady sales growth (+11.5% YoY)

Profit growth

EPS YoY

-120.1%

Earnings shrinking (-120.1% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

7.8%

Modest free cash flow (7.8%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.51%

no trend

Small dividend — 1.51% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial